Antidepressant	O
-	O
Like	O
Effects	O
of	O
Fractions	O
Prepared	O
from	O
Danzhi	O
-	O
Xiaoyao	O
-	O
San	O
Decoction	O
in	O
Rats	B-OG
with	O
Chronic	O
Unpredictable	O
Mild	O
Stress	O
:	O
Effects	O
on	O
Hypothalamic	O
-	O
Pituitary	O
-	O
Adrenal	O
Axis	O
,	O
Arginine	B-GP
Vasopressin	I-GP
,	O
and	O
Neurotransmitters	O

Academic	O
Editor	O
:	O
Maria	O
Camilla	O
Bergonzi	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
two	O
fractions	O
,	O
including	O
petroleum	O
ether	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
)	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
)	O
prepared	O
from	O
the	O
Danzhi	O
-	O
xiaoyao	O
-	O
san	O
(	O
DZXYS	O
)	O
by	O
using	O
chronic	O
unpredictable	O
mild	O
stress	O
-	O
induced	O
depressive	O
rat	B-OG
model	O
.	O

The	O
results	O
indicated	O
that	O
DZXYS	O
could	O
ameliorate	O
the	O
depression	B-DS
-	O
like	O
behavior	O
in	O
chronic	O
stress	O
model	O
of	O
rats	B-OG
.	O

The	O
inhibition	O
of	O
hyperactivity	O
of	O
HPA	O
axis	O
and	O
the	O
modulation	O
of	O
monoamine	O
and	O
amino	O
acid	O
neurotransmitters	O
in	O
the	O
hippocampus	O
may	O
be	O
the	O
important	O
mechanisms	O
underlying	O
the	O
action	O
of	O
DZXYS	O
antidepressant	O
-	O
like	O
effect	O
in	O
chronically	O
stressed	O
rats	B-OG
.	O

1	O
.	O

Introduction	O

Depression	B-DS
is	O
the	O
commonest	O
psychiatric	B-DS
disorder	I-DS
with	O
such	O
main	O
clinical	O
features	O
as	O
significant	O
and	O
lasting	O
depression	B-DS
,	O
mental	O
retardation	O
,	O
cognitive	O
impairment	O
,	O
and	O
depression	B-DS
and	O
somatic	O
symptoms	O
.	O

Furthermore	O
,	O
depression	B-DS
is	O
a	O
risk	O
factor	O
for	O
the	O
onset	O
of	O
type	B-DS
2	I-DS
diabetes	I-DS
mellitus	I-DS
,	O
hypertension	B-DS
,	O
coronary	B-DS
heart	I-DS
disease	I-DS
,	O
cancer	B-DS
,	O
and	O
so	O
on	O
[	O
1	O
],	O
which	O
is	O
projected	O
to	O
become	O
the	O
second	O
biggest	O
contributor	O
to	O
the	O
global	O
burden	O
of	O
disease	O
and	O
disability	O
by	O
2020	O
according	O
to	O
WHO	O
'	O
s	O
prediction	O
.	O

Monoamine	B-DS
neurotransmitters	I-DS
disorder	I-DS
and	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
hyperactivity	O
,	O
widely	O
recognized	O
,	O
are	O
the	O
two	O
important	O
mechanisms	O
of	O
the	O
occurrence	O
of	O
depression	B-DS
.	O

At	O
present	O
,	O
based	O
on	O
the	O
hypothesis	O
of	O
monoamine	O
neurotransmitters	O
function	O
deficiency	O
,	O
antidepression	O
drugs	O
,	O
such	O
as	O
the	O
tricyclic	O
antidepressants	O
(	O
TCAs	O
),	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
),	O
the	O
selective	O
norepinephrine	O
reuptake	O
inhibitors	O
(	O
SNRIs	O
),	O
the	O
selective	O
norepinephrine	O
-	O
dopamine	O
reuptake	O
inhibitors	O
,	O
and	O
the	O
monoamine	B-GP
oxidase	I-GP
inhibitors	O
(	O
MAOIs	O
),	O
have	O
been	O
developed	O
,	O
which	O
are	O
mainly	O
by	O
inhibiting	O
the	O
transporter	O
function	O
of	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
),	O
dopamine	O
(	O
DA	O
),	O
and	O
norepinephrine	O
(	O
NE	O
)	O
to	O
block	O
the	O
reuptake	O
of	O
monoamine	O
neurotransmitters	O
to	O
increase	O
the	O
concentration	O
of	O
those	O
neurotransmitters	O
mentioned	O
above	O
in	O
synaptic	O
cleft	O
to	O
improve	O
the	O
symptoms	O
of	O
depression	B-DS
.	O

But	O
now	O
,	O
the	O
efficacy	O
of	O
those	O
drugs	O
has	O
been	O
faced	O
with	O
serious	O
challenges	O
[	O
2	O
].	O

It	O
is	O
noted	O
that	O
inhibition	O
of	O
HPA	O
axis	O
activity	O
is	O
a	O
very	O
effective	O
antidepressant	O
treatment	O
,	O
but	O
so	O
far	O
new	O
antidepression	O
drugs	O
taking	O
the	O
HPA	O
axis	O
as	O
the	O
target	O
have	O
not	O
been	O
successfully	O
tested	O
by	O
the	O
clinical	O
trials	O
[	O
3	O
].	O

Therefore	O
,	O
the	O
need	O
for	O
more	O
effective	O
and	O
safer	O
antidepression	O
drugs	O
continues	O
to	O
command	O
attention	O
in	O
neuropsychopharmacology	O
within	O
the	O
psychotherapeutic	O
community	O
.	O

Nowadays	O
,	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
has	O
offered	O
prospective	O
alternative	O
therapy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

The	O
records	O
of	O
treating	O
mental	B-DS
disorders	I-DS
could	O
be	O
found	O
in	O
ancient	O
medicinal	O
books	O
,	O
and	O
herbal	O
decoction	O
Danzhi	O
-	O
xiaoyao	O
-	O
san	O
(	O
DZXYS	O
),	O
also	O
called	O
Jiawei	O
-	O
xiaoyao	O
-	O
san	O
,	O
is	O
one	O
of	O
the	O
most	O
popular	O
classical	O
ones	O
.	O

The	O
first	O
description	O
of	O
DZXYS	O
is	O
recorded	O
in	O
Jiaozhu	O
Furen	O
Liangfang	O
“	O
Edited	O
and	O
Commented	O
Effective	O
Formulae	O
for	O
Woman	O
”	O
written	O
by	O
Xue	O
Yi	O
(	O
1487	O
–	O
1559	O
)	O
in	O
Ming	O
Dynasty	O
.	O

This	O
herbal	O
formula	O
is	O
composed	O
of	O
the	O
following	O
herbs	O
:	O
Radix	O
Bupleuri	O
,	O
Paeoniae	B-OG
Radix	O
Alba	O
,	O
Angelica	B-OG
sinensis	I-OG
,	O
bighead	O
atractylodes	B-OG
rhizome	O
,	O
Poria	B-OG
cocos	I-OG
,	O
bark	O
of	O
tree	B-OG
peony	I-OG
root	O
,	O
Fructus	O
Gardeniae	B-OG
,	O
Mentha	B-OG
haplocalyx	I-OG
,	O
and	O
Licorice	B-OG
.	O

It	O
is	O
well	O
known	O
that	O
DZXYS	O
decoction	O
plays	O
an	O
important	O
role	O
in	O
the	O
clinical	O
therapy	O
of	O
depression	B-DS
-	I-DS
related	I-DS
disorders	I-DS
in	O
China	O
[	O
4	O
,	O
5	O
].	O

In	O
Chinese	O
medicinal	O
theory	O
,	O
DZXYS	O
decoction	O
exhibits	O
therapeutic	O
effects	O
by	O
releasing	O
constraint	O
and	O
encouraging	O
the	O
free	O
-	O
flow	O
of	O
liver	O
qi	O
,	O
clearing	O
liver	O
heat	O
,	O
nourishing	O
blood	O
,	O
and	O
invigorating	O
spleen	O
.	O

Although	O
this	O
decoction	O
has	O
been	O
used	O
frequently	O
,	O
thus	O
far	O
,	O
it	O
remains	O
unclear	O
as	O
to	O
which	O
active	O
fraction	O
of	O
the	O
DZXYS	O
is	O
responsible	O
for	O
the	O
antidepressant	O
effect	O
and	O
its	O
possible	O
regulatory	O
mechanism	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
two	O
fractions	O
,	O
including	O
petroleum	O
ether	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
)	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
)	O
prepared	O
from	O
the	O
DZXYS	O
by	O
using	O
chronic	O
unpredictable	O
mild	O
stress	O
-	O
(	O
CUMS	O
-)	O
induced	O
depressive	O
rat	B-OG
model	O
.	O

The	O
underlying	O
mechanism	O
of	O
antidepression	O
was	O
mainly	O
explored	O
by	O
measuring	O
the	O
function	O
of	O
HPA	O
axis	O
and	O
the	O
contents	O
of	O
monoamine	O
and	O
amino	O
acid	O
neurotransmitters	O
in	O
hippocampus	O
.	O

In	O
addition	O
,	O
as	O
a	O
neuropeptide	O
,	O
the	O
arginine	B-GP
vasopressin	I-GP
(	O
AVP	B-GP
)	O
contents	O
in	O
plasma	O
and	O
hypothalamus	O
were	O
detected	O
in	O
the	O
study	O
in	O
order	O
to	O
further	O
explore	O
the	O
antidepressant	O
mechanisms	O
of	O
DZXYS	O
in	O
modulating	O
HPA	O
axis	O
.	O

2	O
.	O

Materials	O
and	O
Methods	O

2	O
.	O
1	O
.	O

Plant	B-OG
Materials	O

Medical	O
plants	B-OG
(	O
dried	O
crude	O
herbs	O
)	O
used	O
for	O
preparation	O
of	O
DZXYS	O
were	O
purchased	O
from	O
Medicinal	O
Materials	O
Company	O
of	O
Guangzhou	O
,	O
Guangzhou	O
,	O
China	O
,	O
and	O
authenticated	O
by	O
Professor	O
Ming	O
-	O
Ping	O
Liu	O
,	O
Chinese	O
Materia	O
Medica	O
College	O
,	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
.	O

DZXYS	O
consists	O
of	O
nine	O
dried	O
crude	O
herbs	O
listed	O
in	O
Table	O
1	O
.	O

The	O
ratio	O
of	O
Radix	O
Bupleuri	O
,	O
Paeoniae	B-OG
Radix	O
Alba	O
,	O
Angelica	B-OG
sinensis	I-OG
,	O
bighead	O
atractylodes	B-OG
rhizome	O
,	O
Poria	B-OG
cocos	I-OG
,	O
bark	O
of	O
tree	B-OG
peony	I-OG
root	O
,	O
Fructus	O
Gardeniae	B-OG
,	O
Mentha	B-OG
haplocalyx	I-OG
,	O
and	O
Licorice	B-OG
is	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
2	O
:	O
1	O
:	O
1	O
.	O

The	O
voucher	O
specimens	O
were	O
conserved	O
at	O
the	O
herbal	O
herbarium	O
of	O
Chinese	O
Materia	O
Medica	O
College	O
,	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Guangzhou	O
,	O
China	O
.	O

The	O
voucher	O
specimens	O
of	O
the	O
herbal	O
materials	O
were	O
deposited	O
for	O
possible	O
future	O
comparison	O
.	O

2	O
.	O
2	O
.	O

Preparation	O
of	O
Fractions	O
from	O
DZXYS	O

The	O
crude	O
powdered	O
mixture	O
of	O
DZXYS	O
,	O
5000	O
g	O
,	O
according	O
to	O
the	O
prescription	O
proportion	O
,	O
was	O
added	O
with	O
petroleum	O
ether	O
(	O
bp	O
60	O
–	O
90	O
°	O
C	O
)	O
and	O
then	O
water	O
-	O
bath	O
-	O
heated	O
and	O
refluxed	O
for	O
4	O
times	O
(	O
2	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
and	O
1	O
.	O
5	O
h	O
);	O
the	O
petroleum	O
-	O
soluble	O
fraction	O
(	O
Fraction	O
A	O
,	O
FA	O
,	O
yield	O
:	O
1	O
.	O
24	O
%)	O
and	O
precipitate	O
were	O
obtained	O
.	O

The	O
precipitate	O
was	O
extracted	O
for	O
3	O
times	O
(	O
2	O
h	O
,	O
1	O
.	O
5	O
h	O
,	O
and	O
1	O
.	O
5	O
h	O
)	O
with	O
boiling	O
water	O
,	O
and	O
then	O
the	O
combined	O
water	O
extracts	O
were	O
filtered	O
and	O
concentrated	O
to	O
2500	O
mL	O
solution	O
which	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
and	O
fractionated	O
by	O
the	O
addition	O
of	O
1710	O
mL	O
of	O
95	O
%	O
ethyl	O
alcohol	O
(	O
EtOH	O
)	O
to	O
give	O
a	O
water	O
-	O
EtOH	O
soluble	O
supernatant	O
fraction	O
(	O
Fraction	O
B	O
,	O
FB	O
,	O
the	O
yield	O
:	O
25	O
.	O
9	O
%).	O

FA	O
and	O
FB	O
were	O
lyophilized	O
into	O
dry	O
powders	O
.	O

In	O
this	O
paper	O
,	O
the	O
doses	O
of	O
FA	O
and	O
FB	O
were	O
expressed	O
in	O
terms	O
of	O
dried	O
weight	O
of	O
herbal	O
material	O
used	O
for	O
extraction	O
per	O
unit	O
body	O
weight	O
of	O
experimental	O
rats	B-OG
(	O
g	O
/	O
kg	O
).	O

2	O
.	O
3	O
.	O

Drugs	O
,	O
Reagents	O
,	O
and	O
Chemicals	O

Imipramine	O
hydrochloride	O
(	O
IMI	O
)	O
was	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

The	O
assay	O
kits	O
of	O
corticosterone	O
(	O
CORT	O
),	O
corticotrophin	B-GP
-	I-GP
releasing	I-GP
hormone	I-GP
(	O
CRH	B-GP
),	O
adrenocorticotropin	B-GP
(	O
ACTH	B-GP
),	O
and	O
arginine	B-GP
vasopressin	I-GP
(	O
AVP	B-GP
)	O
were	O
purchased	O
from	O
Nanjing	O
Jiancheng	O
Institute	O
of	O
Biotechnology	O
,	O
Nanjing	O
,	O
China	O
.	O

The	O
standard	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
),	O
dopamine	O
(	O
DA	O
),	O
and	O
norepinephrine	O
(	O
NE	O
)	O
were	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

Disodium	O
ethylenediaminetetraacetate	O
(	O
EDTA	O
)	O
and	O
the	O
standard	O
amino	O
acids	O
including	O
glutamic	O
acid	O
(	O
Glu	O
),	O
aspartic	O
acid	O
(	O
Asp	O
),	O
γ	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
),	O
and	O
taurine	O
(	O
Tau	O
)	O
were	O
obtained	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

All	O
other	O
reagents	O
used	O
were	O
of	O
analytical	O
grade	O
.	O

2	O
.	O
4	O
.	O

Experimental	O
Animals	B-OG

Male	O
Wistar	B-OG
rats	I-OG
weighing	O
180	O
–	O
220	O
g	O
were	O
purchased	O
from	O
the	O
Laboratory	O
Animal	O
Center	O
of	O
Nanfang	O
Medical	O
University	O
,	O
Guangzhou	O
,	O
China	O
.	O

Animals	B-OG
were	O
allowed	O
1	O
week	O
to	O
adapt	O
to	O
the	O
surroundings	O
before	O
beginning	O
any	O
experimentation	O
.	O

Animals	B-OG
were	O
maintained	O
on	O
a	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
under	O
controlled	O
temperature	O
of	O
22	O
±	O
2	O
°	O
C	O
and	O
had	O
free	O
access	O
to	O
food	O
and	O
water	O
.	O

All	O
animals	B-OG
handling	O
procedures	O
were	O
performed	O
in	O
strict	O
accordance	O
with	O
the	O
China	O
legislation	O
on	O
the	O
use	O
and	O
care	O
of	O
laboratory	O
animals	B-OG
and	O
were	O
approved	O
by	O
the	O
Animal	O
Experimentation	O
Ethics	O
Committee	O
of	O
the	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
.	O

All	O
efforts	O
were	O
made	O
to	O
minimize	O
the	O
number	O
and	O
suffering	O
of	O
animals	B-OG
needed	O
to	O
produce	O
reliable	O
data	O
.	O

2	O
.	O
5	O
.	O

Chronic	O
Unpredictable	O
Mild	O
Stress	O
(	O
CUMS	O
)	O

The	O
stress	O
procedure	O
performed	O
here	O
mainly	O
referred	O
to	O
Willner	O
[	O
6	O
]	O
with	O
some	O
modifications	O
.	O

Briefly	O
,	O
the	O
CUMS	O
protocol	O
consisted	O
of	O
the	O
sequential	O
application	O
of	O
a	O
variety	O
of	O
unpredictable	O
mild	O
stressors	O
:	O
(	O
1	O
)	O
food	O
deprivation	O
for	O
24	O
hours	O
,	O
(	O
2	O
)	O
water	O
deprivation	O
for	O
24	O
hours	O
,	O
(	O
3	O
)	O
exposure	O
to	O
an	O
empty	O
bottle	O
for	O
1	O
hour	O
,	O
(	O
4	O
)	O
cage	O
tilt	O
(	O
45	O
°)	O
for	O
7	O
hours	O
,	O
(	O
5	O
)	O
overnight	O
illumination	O
,	O
(	O
6	O
)	O
soiled	O
cage	O
(	O
200	O
mL	O
water	O
in	O
100	O
g	O
sawdust	O
bedding	O
)	O
for	O
24	O
hours	O
,	O
(	O
7	O
)	O
forced	O
swimming	O
at	O
8	O
°	O
C	O
for	O
6	O
minutes	O
,	O
(	O
8	O
)	O
physical	O
restraint	O
for	O
2	O
hours	O
,	O
and	O
(	O
9	O
)	O
exposure	O
to	O
a	O
foreign	O
object	O
(	O
e	O
.	O
g	O
.,	O
a	O
piece	O
of	O
plastic	O
)	O
for	O
24	O
hours	O
.	O

These	O
stressors	O
were	O
randomly	O
scheduled	O
over	O
a	O
one	O
-	O
week	O
period	O
and	O
repeated	O
throughout	O
the	O
4	O
weeks	O
of	O
experiment	O
(	O
Figure	O
1	O
).	O

Nonstressed	O
animals	B-OG
were	O
left	O
undisturbed	O
in	O
their	O
home	O
cages	O
except	O
during	O
housekeeping	O
procedures	O
such	O
as	O
cage	O
cleaning	O
.	O

2	O
.	O
6	O
.	O

Treatment	O
of	O
Animals	B-OG

In	O
experiments	O
,	O
animals	B-OG
were	O
randomized	O
into	O
seven	O
groups	O
of	O
ten	O
individuals	O
.	O

The	O
control	O
animals	B-OG
were	O
unstressed	O
and	O
intragastrically	O
given	O
daily	O
2	O
mL	O
distilled	O
water	O
.	O

For	O
another	O
six	O
groups	O
,	O
the	O
animals	B-OG
were	O
treated	O
simultaneously	O
with	O
CUMS	O
.	O

The	O
drugs	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
/	O
day	O
,	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
and	O
IMI	O
at	O
20	O
mg	O
/	O
kg	O
/	O
day	O
,	O
suspended	O
in	O
distilled	O
water	O
)	O
were	O
intragastrically	O
given	O
daily	O
1	O
h	O
before	O
the	O
stress	O
exposure	O
for	O
the	O
entire	O
4	O
weeks	O
.	O

Following	O
each	O
stress	O
session	O
,	O
animals	B-OG
were	O
returned	O
to	O
their	O
home	O
cages	O
and	O
were	O
able	O
to	O
access	O
food	O
and	O
water	O
freely	O
for	O
the	O
remainder	O
of	O
the	O
day	O
.	O

2	O
.	O
7	O
.	O

Rat	B-OG
Sucrose	O
Preference	O
Test	O

Sucrose	O
preference	O
test	O
was	O
carried	O
out	O
at	O
the	O
end	O
of	O
4	O
-	O
week	O
CUMS	O
exposure	O
.	O

The	O
test	O
was	O
performed	O
as	O
described	O
previously	O
[	O
7	O
]	O
with	O
minor	O
modifications	O
.	O

Briefly	O
,	O
after	O
one	O
week	O
of	O
the	O
single	O
cage	O
feeding	O
adaptation	O
,	O
the	O
rats	B-OG
received	O
a	O
week	O
of	O
double	O
bottle	O
training	O
.	O

One	O
bottle	O
was	O
1	O
%	O
sucrose	O
solution	O
(	O
w	O
/	O
v	O
)	O
100	O
mL	O
(	O
in	O
the	O
cage	O
on	O
the	O
left	O
),	O
another	O
was	O
pure	O
water	O
100	O
mL	O
(	O
in	O
the	O
cage	O
on	O
the	O
right	O
),	O
and	O
two	O
bottles	O
were	O
fixed	O
.	O

Sucrose	O
solution	O
and	O
pure	O
water	O
were	O
added	O
every	O
morning	O
.	O

After	O
one	O
-	O
week	O
training	O
,	O
the	O
rats	B-OG
were	O
deprived	O
of	O
water	O
and	O
food	O
for	O
24	O
hours	O
,	O
and	O
then	O
1	O
h	O
sucrose	O
solution	O
consumption	O
experiments	O
were	O
conducted	O
to	O
measure	O
the	O
basis	O
of	O
sucrose	O
preference	O
at	O
9	O
:	O
00	O
am	O
in	O
which	O
rats	B-OG
were	O
housed	O
in	O
individual	O
cages	O
and	O
were	O
free	O
to	O
access	O
two	O
bottles	O
.	O

After	O
4	O
weeks	O
of	O
experiment	O
,	O
the	O
sucrose	O
preference	O
was	O
conducted	O
again	O
by	O
the	O
method	O
described	O
above	O
.	O

The	O
sucrose	O
preference	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
sucrose	O
preference	O
(%)	O
=	O
sucrose	O
consumption	O
/	O
total	O
liquid	O
consumption	O
×	O
100	O
%	O
[	O
8	O
].	O

2	O
.	O
8	O
.	O

Forced	O
Swimming	O
Test	O
(	O
FST	O
)	O

The	O
forced	O
swimming	O
test	O
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Porsolt	O
[	O
9	O
]	O
with	O
modifications	O
.	O

Briefly	O
,	O
rats	B-OG
were	O
forced	O
to	O
swim	O
in	O
a	O
transparent	O
glass	O
vessel	O
(	O
25	O
cm	O
in	O
height	O
and	O
14	O
cm	O
in	O
diameter	O
)	O
filled	O
with	O
15	O
cm	O
of	O
water	O
at	O
24	O
±	O
1	O
°	O
C	O
.	O

The	O
total	O
duration	O
of	O
immobility	O
(	O
seconds	O
)	O
was	O
measured	O
during	O
the	O
last	O
4	O
minutes	O
of	O
a	O
single	O
6	O
-	O
minute	O
test	O
session	O
[	O
10	O
].	O

Rats	B-OG
were	O
considered	O
immobile	O
when	O
they	O
ceased	O
struggling	O
and	O
remained	O
floating	O
motionless	O
in	O
the	O
water	O
except	O
the	O
movements	O
necessary	O
to	O
keep	O
their	O
heads	O
above	O
the	O
water	O
.	O

Decrease	O
in	O
the	O
duration	O
of	O
immobility	O
during	O
the	O
FST	O
was	O
taken	O
as	O
a	O
measure	O
of	O
antidepressant	O
activity	O
.	O

2	O
.	O
9	O
.	O

Tail	O
Suspension	O
Test	O
(	O
TST	O
)	O

The	O
duration	O
of	O
immobility	O
time	O
induced	O
by	O
tail	O
suspension	O
was	O
measured	O
according	O
to	O
the	O
method	O
of	O
Steru	O
[	O
11	O
].	O

Rats	B-OG
both	O
acoustically	O
and	O
visually	O
isolated	O
were	O
suspended	O
above	O
the	O
floor	O
by	O
adhesive	O
tape	O
placed	O
approximately	O
1	O
cm	O
from	O
the	O
tip	O
of	O
the	O
tail	O
.	O

The	O
remaining	O
immobile	O
time	O
of	O
TST	O
was	O
quantified	O
for	O
6	O
min	O
.	O

Rats	B-OG
were	O
considered	O
immobile	O
only	O
when	O
they	O
hung	O
passively	O
and	O
completely	O
motionless	O
.	O

2	O
.	O
10	O
.	O

Open	O
-	O
Field	O
Test	O
(	O
OFT	O
)	O

The	O
OFT	O
was	O
based	O
on	O
the	O
method	O
of	O
Archer	O
[	O
12	O
].	O

The	O
OFT	O
apparatus	O
consisted	O
of	O
a	O
clear	O
acrylic	O
box	O
(	O
100	O
cm	O
×	O
100	O
cm	O
×	O
50	O
cm	O
)	O
with	O
a	O
lid	O
.	O

The	O
floor	O
was	O
divided	O
by	O
drawn	O
lines	O
into	O
36	O
areas	O
of	O
about	O
25	O
sq	O
.	O
cm	O
.	O

The	O
test	O
was	O
performed	O
in	O
a	O
light	O
-	O
and	O
sound	O
-	O
attenuated	O
shield	O
box	O
with	O
a	O
dim	O
light	O
.	O

The	O
locomotor	O
activity	O
counts	O
and	O
the	O
rearing	O
counts	O
were	O
recorded	O
for	O
5	O
min	O
.	O

All	O
test	O
sessions	O
were	O
recorded	O
by	O
a	O
video	O
camera	O
.	O

Between	O
subjects	O
,	O
the	O
box	O
was	O
thoroughly	O
cleaned	O
with	O
cotton	O
and	O
95	O
%	O
ethanol	O
.	O

2	O
.	O
11	O
.	O

CORT	O
,	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
Contents	O
in	O
Plasma	O
Assays	O

After	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
all	O
rats	B-OG
were	O
sacrificed	O
by	O
decapitation	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
am	O
in	O
the	O
laboratory	O
.	O

After	O
decapitation	O
,	O
the	O
blood	O
samples	O
were	O
collected	O
into	O
heparinized	O
Eppendorf	O
tubes	O
and	O
immediately	O
centrifuged	O
for	O
1	O
min	O
(	O
10	O
,	O
000	O
rpm	O
)	O
at	O
4	O
°	O
C	O
to	O
separate	O
plasma	O
,	O
which	O
was	O
then	O
frozen	O
at	O
−	O
20	O
°	O
C	O
until	O
subsequent	O
assays	O
.	O

CORT	O
,	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
contents	O
in	O
plasma	O
were	O
determined	O
by	O
using	O
competitive	O
radioimmunoassay	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

2	O
.	O
12	O
.	O

CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
Contents	O
in	O
Hypothalamus	O
Assays	O

After	O
decapitation	O
,	O
the	O
brains	O
were	O
rapidly	O
removed	O
and	O
immersed	O
into	O
the	O
boiling	O
saline	O
for	O
5	O
min	O
.	O

Hypothalamus	O
was	O
dissected	O
according	O
to	O
the	O
method	O
described	O
by	O
Yan	O
et	O
al	O
.	O
[	O
13	O
],	O
weighed	O
,	O
and	O
then	O
homogenized	O
in	O
0	O
.	O
2	O
mL	O
of	O
1	O
M	O
acetic	O
acid	O
solution	O
.	O

After	O
incubation	O
for	O
100	O
minutes	O
at	O
room	O
temperature	O
,	O
homogenate	O
solution	O
was	O
mixed	O
with	O
0	O
.	O
2	O
mL	O
of	O
1	O
M	O
NaOH	O
solution	O
and	O
centrifuged	O
for	O
20	O
min	O
(	O
3500	O
rpm	O
)	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatants	O
were	O
collected	O
and	O
stored	O
at	O
−	O
40	O
°	O
C	O
.	O

Radioimmunoassay	O
was	O
performed	O
to	O
measure	O
CRH	B-GP
,	O
ACTH	B-GP
,	O
and	O
AVP	B-GP
in	O
hypothalamus	O
following	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

2	O
.	O
13	O
.	O

Monoamine	O
and	O
Amino	O
Acid	O
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
Determination	O

After	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
all	O
rats	B-OG
were	O
sacrificed	O
by	O
decapitation	O
between	O
10	O
:	O
00	O
and	O
11	O
:	O
00	O
am	O
in	O
the	O
laboratory	O
.	O

After	O
decapitation	O
,	O
the	O
whole	O
rat	B-OG
brains	O
were	O
rapidly	O
removed	O
and	O
the	O
hippocampus	O
was	O
carefully	O
dissected	O
according	O
to	O
the	O
method	O
described	O
previously	O
[	O
14	O
].	O

The	O
contents	O
of	O
5	O
-	O
HT	O
,	O
5	O
-	O
hydroxyindoleacetic	O
acid	O
(	O
5	O
-	O
HIAA	O
),	O
DA	O
,	O
and	O
NE	O
in	O
hippocampus	O
were	O
determined	O
by	O
using	O
an	O
electrochemical	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
EC	O
-	O
HPLC	O
).	O

Tissues	O
were	O
placed	O
in	O
0	O
.	O
1	O
N	O
perchloric	O
acid	O
(	O
including	O
0	O
.	O
1	O
%	O
aminothiopropionic	O
acid	O
),	O
then	O
sonicated	O
,	O
and	O
centrifuged	O
twice	O
for	O
20	O
min	O
at	O
10	O
,	O
000	O
rpm	O
.	O

The	O
supernatants	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
being	O
analyzed	O
for	O
the	O
contents	O
of	O
DA	O
,	O
5	O
-	O
HT	O
,	O
and	O
NE	O
.	O

The	O
pellets	O
were	O
digested	O
in	O
1	O
mL	O
of	O
0	O
.	O
5	O
N	O
NaOH	O
for	O
measurements	O
of	O
protein	O
concentration	O
using	O
Bio	O
-	O
Rad	O
assay	O
reagents	O
.	O

For	O
EC	O
-	O
HPLC	O
analysis	O
,	O
samples	O
were	O
loaded	O
onto	O
a	O
Waters	O
7125	O
plus	O
autosampler	O
(	O
Waters	O
,	O
Milford	O
,	O
USA	O
)	O
and	O
the	O
mobile	O
phase	O
was	O
delivered	O
at	O
a	O
constant	O
rate	O
of	O
1	O
mL	O
/	O
min	O
by	O
a	O
Waters	O
Model	O
515	O
pump	O
(	O
Waters	O
,	O
Milford	O
,	O
USA	O
)	O
through	O
a	O
C18	O
,	O
5	O
mm	O
,	O
250	O
mm	O
×	O
4	O
.	O
6	O
mm	O
analytical	O
column	O
(	O
HiQsil	O
,	O
Japan	O
)	O
placed	O
in	O
a	O
column	O
heater	O
(	O
35	O
°	O
C	O
).	O

The	O
LC	O
amperometric	O
potential	O
was	O
set	O
to	O
0	O
.	O
75	O
V	O
with	O
reference	O
to	O
an	O
Ag	O
-	O
AgCl	O
reference	O
electrode	O
and	O
the	O
sensitivity	O
of	O
the	O
detector	O
was	O
modified	O
according	O
to	O
the	O
content	O
of	O
amines	O
in	O
the	O
sample	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0	O
.	O
1	O
M	O
monosodium	O
phosphate	O
,	O
0	O
.	O
15	O
mM	O
EDTA	O
,	O
2	O
mM	O
NaCl	O
,	O
1	O
.	O
4	O
mM	O
octyl	O
sodium	O
sulfate	O
,	O
and	O
12	O
%	O
methanol	O
.	O

The	O
signal	O
from	O
the	O
detector	O
was	O
recorded	O
and	O
the	O
data	O
was	O
analyzed	O
using	O
a	O
N2000	O
Workstation	O
(	O
Institute	O
of	O
Intelligent	O
Information	O
Engineering	O
,	O
Zhejiang	O
University	O
,	O
Zhejiang	O
,	O
China	O
).	O

The	O
monoamine	O
neurotransmitter	O
contents	O
were	O
expressed	O
as	O
ng	O
/	O
g	O
weight	O
of	O
tissue	O
.	O

Amino	O
acids	O
in	O
hippocampus	O
were	O
determined	O
by	O
OPA	O
precolumn	O
derivatization	O
and	O
RP	O
-	O
HPLC	O
with	O
a	O
high	O
-	O
performance	O
liquid	O
chromatography	O
system	O
(	O
Hewlett	O
-	O
Packed	O
1100	O
series	O
,	O
USA	O
).	O

The	O
derivatization	O
procedure	O
was	O
accomplished	O
by	O
an	O
online	O
autoinjector	O
.	O

The	O
derivatives	O
were	O
separated	O
on	O
a	O
Hypersil	O
ODS	O
and	O
the	O
signals	O
were	O
detected	O
with	O
a	O
programmable	O
fluorospectrophotometer	O
detector	O
.	O

Mobile	O
phase	O
A	O
was	O
10	O
mmol	O
/	O
L	O
,	O
PH	O
7	O
.	O
2	O
sodium	O
phosphate	O
buffer	O
(	O
PB	O
)	O
containing	O
0	O
.	O
5	O
%	O
(	O
φ	O
)	O
tetrahydrofuran	O
,	O
and	O
B	O
was	O
PB	O
-	O
methanol	O
-	O
acetonitrile	O
(	O
50	O
:	O
35	O
:	O
15	O
by	O
volume	O
).	O

The	O
elution	O
program	O
was	O
100	O
%	O
A	O
with	O
0	O
%	O
B	O
at	O
the	O
start	O
(	O
0	O
min	O
)	O
and	O
0	O
%	O
A	O
with	O
100	O
%	O
B	O
at	O
the	O
end	O
(	O
25	O
min	O
)	O
of	O
the	O
program	O
.	O

OPA	O
-	O
reactive	O
compounds	O
were	O
detected	O
at	O
excitation	O
wavelength	O
of	O
340	O
nm	O
and	O
emission	O
wavelength	O
of	O
450	O
nm	O
,	O
and	O
chromatograms	O
were	O
analyzed	O
.	O

2	O
.	O
14	O
.	O

Statistical	O
Analysis	O

The	O
data	O
were	O
expressed	O
as	O
mean	O
±	O
standard	O
deviation	O
(	O
SD	O
).	O

The	O
significance	O
of	O
the	O
difference	O
was	O
statistically	O
evaluated	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
as	O
well	O
as	O
the	O
least	O
significant	O
difference	O
test	O
.	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

3	O
.	O

Results	O

3	O
.	O
1	O
.	O

Sucrose	O
Preference	O
Test	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
CUMS	O
decreased	O
the	O
sucrose	O
preference	O
in	O
rats	B-OG
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
sucrose	O
preference	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
2	O
).	O

3	O
.	O
2	O
.	O

Forced	O
Swimming	O
Test	O
(	O
FST	O
)	O
in	O
Each	O
Group	O

In	O
FST	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
duration	O
of	O
immobility	O
in	O
rats	B-OG
with	O
CUMS	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
duration	O
of	O
immobility	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
3	O
).	O

3	O
.	O
3	O
.	O

Tail	O
Suspension	O
Test	O
(	O
TST	O
)	O
in	O
Each	O
Group	O

In	O
TST	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
duration	O
of	O
immobility	O
in	O
rats	B-OG
with	O
CUMS	O
increased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
duration	O
of	O
immobility	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
Figure	O
4	O
).	O

3	O
.	O
4	O
.	O

Open	O
-	O
Field	O
Test	O
(	O
OFT	O
)	O
in	O
Each	O
Group	O

In	O
the	O
OFT	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
the	O
locomotor	O
activity	O
and	O
the	O
rearing	O
counts	O
for	O
5	O
min	O
were	O
lower	O
in	O
the	O
rats	B-OG
with	O
CUMS	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
results	O
showed	O
that	O
the	O
rats	B-OG
with	O
CUMS	O
appeared	O
to	O
have	O
depressant	O
-	O
like	O
behavioral	O
changes	O
.	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
locomotor	O
activity	O
and	O
the	O
rearing	O
counts	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
5	O
).	O

3	O
.	O
5	O
.	O

CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
Contents	O
in	O
Plasma	O
and	O
Hypothalamus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
2	O
,	O
CUMS	O
significantly	O
increased	O
the	O
contents	O
of	O
CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
plasma	O
in	O
rats	B-OG
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
contents	O
of	O
CRH	B-GP
and	O
ACTH	B-GP
in	O
hypothalamus	O
in	O
rats	B-OG
with	O
CUMS	O
were	O
also	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

Compared	O
with	O
the	O
CUMS	O
group	O
,	O
FA	O
at	O
0	O
.	O
172	O
g	O
/	O
kg	O
,	O
FB	O
at	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
contents	O
in	O
plasma	O
and	O
hypothalamus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
6	O
.	O

AVP	B-GP
Contents	O
in	O
Plasma	O
and	O
Hypothalamus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
3	O
,	O
CUMS	O
significantly	O
increased	O
the	O
AVP	B-GP
contents	O
both	O
in	O
hypothalamus	O
and	O
in	O
plasma	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
AVP	B-GP
contents	O
could	O
be	O
significantly	O
decreased	O
in	O
both	O
hypothalamus	O
and	O
plasma	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

3	O
.	O
7	O
.	O

Monoamine	O
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
in	O
Each	O
Group	O

As	O
shown	O
in	O
Table	O
4	O
and	O
Figures	O
6	O
and	O
7	O
,	O
compared	O
with	O
the	O
control	O
group	O
,	O
CUMS	O
markedly	O
decreased	O
the	O
contents	O
of	O
5	O
-	O
HT	O
and	O
DA	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
increased	O
the	O
NE	O
content	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
01	O
).	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
contents	O
of	O
5	O
-	O
HT	O
and	O
DA	O
and	O
decreased	O
the	O
content	O
of	O
NE	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

As	O
a	O
positive	O
control	O
,	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
could	O
increase	O
the	O
5	O
-	O
HT	O
content	O
and	O
decrease	O
the	O
NE	O
content	O
in	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
but	O
had	O
no	O
effect	O
on	O
DA	O
.	O

As	O
a	O
metabolite	O
of	O
serotonin	O
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
could	O
be	O
used	O
as	O
an	O
index	O
for	O
the	O
turnover	O
of	O
5	O
-	O
HT	O
[	O
15	O
,	O
16	O
].	O

Here	O
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
was	O
calculated	O
.	O

The	O
amount	O
of	O
5	O
-	O
HIAA	O
was	O
not	O
altered	O
in	O
hippocampus	O
of	O
rat	B-OG
with	O
CUMS	O
(	O
Table	O
4	O
).	O

FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
as	O
well	O
as	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
elevated	O
the	O
amount	O
of	O
5	O
-	O
HIAA	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

The	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
significantly	O
increased	O
by	O
CUMS	O
,	O
which	O
could	O
be	O
reversed	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
).	O

3	O
.	O
8	O
.	O

Amino	O
Acid	O
Neurotransmitters	O
Contents	O
in	O
Hippocampus	O
in	O
Each	O
Group	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
while	O
the	O
GABA	O
and	O
Tau	O
contents	O
were	O
significantly	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
the	O
hippocampus	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
,	O
Figure	O
8	O
)	O
but	O
had	O
no	O
effects	O
on	O
GABA	O
and	O
Tau	O
.	O

4	O
.	O

Discussion	O

Traditional	O
Chinese	O
medicine	O
has	O
offered	O
a	O
possible	O
therapy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

DZXYS	O
,	O
an	O
ancient	O
Chinese	O
herbal	O
decoction	O
,	O
has	O
been	O
used	O
in	O
Chinese	O
medicinal	O
herbal	O
mixture	O
for	O
antidepression	O
.	O

However	O
,	O
its	O
action	O
mechanism	O
has	O
not	O
been	O
revealed	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
provided	O
different	O
lines	O
of	O
evidence	O
to	O
support	O
the	O
antidepression	O
role	O
of	O
DZXYS	O
in	O
CUMS	O
rat	B-OG
model	O
system	O
.	O

The	O
pathogenesis	O
of	O
depression	B-DS
model	O
established	O
by	O
using	O
stress	O
factors	O
is	O
more	O
consistent	O
with	O
that	O
of	O
depression	B-DS
in	O
human	B-OG
beings	O
.	O

The	O
symptoms	O
such	O
as	O
reduced	O
activity	O
,	O
decreased	O
exploratory	O
behavior	O
,	O
and	O
reduced	O
sucrose	O
preference	O
appear	O
in	O
stressed	O
animals	B-OG
,	O
which	O
are	O
similar	O
to	O
the	O
changes	O
of	O
behavior	O
and	O
the	O
loss	O
of	O
interest	O
or	O
pleasure	O
in	O
the	O
clinical	O
diagnosis	O
of	O
depression	B-DS
[	O
17	O
].	O

The	O
CUMS	O
model	O
of	O
depression	B-DS
is	O
accepted	O
as	O
a	O
valuable	O
method	O
for	O
evaluating	O
antidepressant	O
effects	O
in	O
animals	B-OG
.	O

In	O
the	O
present	O
study	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
prepared	O
from	O
DZXYS	O
exhibited	O
a	O
significant	O
increase	O
of	O
sucrose	O
preference	O
in	O
the	O
rats	B-OG
with	O
CUMS	O
.	O

The	O
FST	O
,	O
TST	O
,	O
and	O
OFT	O
are	O
the	O
most	O
widely	O
used	O
as	O
behavioral	O
tools	O
for	O
assessing	O
antidepressant	O
activity	O
[	O
18	O
,	O
19	O
].	O

Characteristic	O
of	O
rat	B-OG
behaviors	O
scored	O
in	O
both	O
tests	O
is	O
termed	O
immobility	O
,	O
which	O
reflects	O
behavioral	O
despair	O
as	O
seen	O
in	O
human	B-OG
depression	B-DS
.	O

The	O
duration	O
of	O
immobility	O
time	O
in	O
rats	B-OG
that	O
are	O
trapped	O
and	O
forced	O
to	O
swim	O
is	O
closely	O
related	O
to	O
helplessness	O
[	O
20	O
].	O

It	O
was	O
observed	O
from	O
our	O
results	O
that	O
there	O
was	O
significant	O
prolongation	O
of	O
immobility	O
time	O
in	O
these	O
groups	O
after	O
modeling	O
.	O

The	O
two	O
fractions	O
at	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
respectively	O
,	O
could	O
significantly	O
decrease	O
the	O
duration	O
of	O
immobility	O
both	O
in	O
FST	O
and	O
in	O
TST	O
and	O
significantly	O
increase	O
the	O
locomotor	O
activity	O
in	O
OFT	O
.	O

These	O
results	O
may	O
further	O
confirm	O
that	O
the	O
DZXYS	O
has	O
an	O
antidepressant	O
activity	O
.	O

The	O
nervous	O
system	O
and	O
the	O
endocrine	O
system	O
are	O
closely	O
related	O
,	O
which	O
constitute	O
a	O
complete	O
network	O
to	O
maintain	O
homeostasis	O
.	O

HPA	O
axis	O
activation	O
and	O
the	O
resulting	O
increase	O
in	O
glucocorticoid	O
(	O
GC	O
)	O
secretion	O
are	O
the	O
two	O
most	O
important	O
features	O
of	O
the	O
stress	O
response	O
.	O

When	O
in	O
stress	O
state	O
,	O
the	O
hypothalamus	O
releases	O
CRH	B-GP
and	O
AVP	B-GP
in	O
response	O
to	O
a	O
stressor	O
,	O
which	O
in	O
turn	O
activate	O
the	O
secretion	O
of	O
ACTH	B-GP
from	O
the	O
pituitary	O
,	O
which	O
finally	O
stimulates	O
the	O
secretion	O
of	O
cortisol	O
(	O
in	O
humans	B-OG
)	O
or	O
CORT	O
(	O
in	O
rodents	B-OG
)	O
from	O
the	O
adrenal	O
cortex	O
[	O
21	O
].	O

From	O
the	O
actual	O
situation	O
of	O
human	B-OG
depression	B-DS
,	O
stressful	O
life	O
events	O
play	O
an	O
important	O
role	O
in	O
depression	B-DS
.	O

Stressor	O
or	O
stressful	O
environment	O
usually	O
precedes	O
depressive	O
symptoms	O
,	O
which	O
leads	O
to	O
neurobiochemical	O
changes	O
associated	O
with	O
depression	B-DS
[	O
17	O
].	O

Since	O
the	O
1970s	O
,	O
people	O
have	O
found	O
that	O
the	O
HPA	O
axis	O
is	O
involved	O
in	O
the	O
pathological	O
mechanism	O
of	O
depression	B-DS
.	O

Many	O
studies	O
suggested	O
that	O
HPA	O
axis	O
activation	O
results	O
in	O
some	O
of	O
the	O
symptoms	O
and	O
signs	O
in	O
depression	B-DS
[	O
22	O
].	O

Moreover	O
,	O
it	O
has	O
been	O
found	O
that	O
the	O
damage	O
of	O
HPA	O
axis	O
is	O
more	O
severe	O
in	O
patients	O
with	O
refractory	B-DS
depression	I-DS
[	O
23	O
].	O

Hyperactivity	O
of	O
HPA	O
axis	O
often	O
occurs	O
in	O
both	O
depressed	O
patients	O
and	O
animal	B-OG
models	O
,	O
which	O
is	O
mainly	O
presented	O
as	O
hypersecreted	O
CRH	B-GP
and	O
higher	O
contents	O
of	O
ACTH	B-GP
and	O
GC	O
[	O
24	O
,	O
25	O
].	O

Combined	O
with	O
receptors	O
in	O
multiple	O
target	O
tissues	O
(	O
including	O
HPA	O
axis	O
),	O
GC	O
could	O
exert	O
physiological	O
effects	O
.	O

When	O
in	O
state	O
of	O
stress	O
,	O
GC	O
is	O
hypersecreted	O
and	O
then	O
combined	O
with	O
glucocorticoid	B-GP
receptor	I-GP
(	O
GR	B-GP
),	O
thereby	O
inhibiting	O
the	O
hypothalamus	O
to	O
secrete	O
CRF	B-GP
and	O
AVP	B-GP
by	O
negative	O
feedback	O
to	O
restore	O
the	O
hyperactivated	O
HPA	O
axis	O
to	O
the	O
basal	O
level	O
.	O

However	O
,	O
chronic	O
stress	O
could	O
result	O
in	O
the	O
state	O
of	O
persistent	O
hyperactivity	O
of	O
the	O
HPA	O
axis	O
;	O
excessive	O
GC	O
constantly	O
stimulates	O
GR	B-GP
,	O
which	O
leads	O
to	O
the	O
injury	O
of	O
hippocampal	O
neurons	O
and	O
the	O
dysfunction	O
of	O
emotion	O
regulation	O
center	O
,	O
and	O
then	O
induces	O
depression	B-DS
[	O
26	O
].	O

As	O
observed	O
in	O
our	O
experiment	O
,	O
the	O
CUMS	O
could	O
significantly	O
increase	O
the	O
contents	O
of	O
CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
both	O
plasma	O
and	O
hypothalamus	O
in	O
rats	B-OG
,	O
accompanied	O
by	O
the	O
depressive	O
-	O
like	O
behavioral	O
alterations	O
;	O
thus	O
,	O
we	O
confirmed	O
that	O
HPA	O
axis	O
hyperactivity	O
is	O
related	O
to	O
the	O
pathogenesis	O
of	O
depression	B-DS
.	O

Results	O
from	O
the	O
present	O
study	O
demonstrated	O
that	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
prepared	O
from	O
DZXYS	O
could	O
significantly	O
decrease	O
the	O
CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
contents	O
in	O
plasma	O
and	O
hypothalamus	O
,	O
which	O
suggested	O
that	O
antidepressant	O
effects	O
exerted	O
by	O
DZXYS	O
were	O
partly	O
due	O
to	O
inhibiting	O
the	O
hyperactivity	O
of	O
the	O
HPA	O
axis	O
.	O

Some	O
previous	O
studies	O
have	O
shown	O
that	O
there	O
are	O
significant	O
increases	O
of	O
AVP	B-GP
neurons	O
expression	O
and	O
AVP	B-GP
level	O
in	O
the	O
paraventricular	O
nucleus	O
,	O
AVP	B-GP
reactivity	O
in	O
the	O
pituitary	O
,	O
and	O
AVP	B-GP
mRNA	O
expression	O
in	O
the	O
supraoptic	O
nucleus	O
in	O
depressed	O
patients	O
[	O
27	O
,	O
28	O
],	O
which	O
also	O
suggests	O
that	O
AVP	B-GP
changes	O
in	O
the	O
paraventricular	O
nucleus	O
and	O
supraoptic	O
nucleus	O
may	O
be	O
the	O
basis	O
for	O
the	O
onset	O
of	O
depression	B-DS
.	O

In	O
addition	O
,	O
AVP	B-GP
level	O
in	O
the	O
plasma	O
in	O
depressed	O
patients	O
is	O
higher	O
than	O
that	O
in	O
the	O
healthy	O
control	O
group	O
,	O
which	O
is	O
related	O
to	O
the	O
severity	O
of	O
the	O
disease	O
[	O
29	O
].	O

AVP	B-GP
,	O
a	O
nonapeptide	O
synthesized	O
in	O
hypothalamic	O
nuclei	O
,	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
HPA	O
axis	O
representing	O
a	O
major	O
component	O
of	O
the	O
stress	O
response	O
.	O

CRH	B-GP
and	O
AVP	B-GP
act	O
synergistically	O
in	O
bringing	O
about	O
ACTH	B-GP
release	O
from	O
the	O
corticotropes	O
of	O
the	O
anterior	O
pituitary	O
,	O
which	O
in	O
turn	O
stimulates	O
cortisol	O
output	O
from	O
the	O
adrenal	O
cortex	O
.	O

AVP	B-GP
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
depression	B-DS
by	O
regulating	O
the	O
HPA	O
axis	O
function	O
[	O
30	O
].	O

In	O
order	O
to	O
further	O
explore	O
the	O
effect	O
of	O
DZXYS	O
on	O
HPA	O
axis	O
,	O
the	O
levels	O
of	O
AVP	B-GP
in	O
plasma	O
and	O
hypothalamus	O
were	O
measured	O
in	O
the	O
present	O
study	O
.	O

Our	O
results	O
showed	O
that	O
,	O
in	O
rats	B-OG
with	O
CUMS	O
,	O
AVP	B-GP
levels	O
significantly	O
increased	O
in	O
plasma	O
and	O
hypothalamus	O
,	O
which	O
could	O
be	O
significantly	O
reversed	O
by	O
the	O
treatment	O
of	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
),	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
and	O
IMI	O
(	O
20	O
mg	O
/	O
kg	O
).	O

Combined	O
with	O
the	O
results	O
of	O
HPA	O
axis	O
determination	O
in	O
our	O
study	O
,	O
it	O
suggested	O
that	O
DZXYS	O
could	O
regulate	O
the	O
HPA	O
axis	O
by	O
acting	O
on	O
the	O
AVP	B-GP
to	O
exert	O
antidepressant	O
effect	O
.	O

As	O
a	O
significant	O
contribution	O
to	O
depression	B-DS
,	O
“	O
monoamine	O
hypothesis	O
”	O
has	O
been	O
proposed	O
in	O
the	O
20th	O
century	O
,	O
thereby	O
setting	O
up	O
the	O
foundation	O
for	O
today	O
'	O
s	O
antidepressant	O
treatment	O
.	O

Monoamine	O
neurotransmitters	O
,	O
such	O
as	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
,	O
are	O
the	O
important	O
bioactive	O
substances	O
in	O
central	O
nervous	O
system	O
which	O
participate	O
in	O
many	O
physiological	O
activities	O
of	O
the	O
body	O
,	O
including	O
emotion	O
,	O
learning	O
,	O
and	O
memory	O
.	O

NE	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
arousal	O
and	O
is	O
involved	O
in	O
the	O
brain	O
reward	O
system	O
and	O
learning	O
and	O
memory	O
function	O
.	O

The	O
concentration	O
of	O
NE	O
in	O
the	O
hypothalamus	O
is	O
significantly	O
decreased	O
,	O
which	O
suggests	O
that	O
the	O
dysfunction	O
of	O
central	O
NE	O
is	O
related	O
to	O
depression	B-DS
[	O
31	O
].	O

Dysfunction	O
of	O
5	O
-	O
HT	O
is	O
related	O
to	O
depressed	O
mood	O
,	O
anxiety	B-DS
,	O
inhibition	O
of	O
movement	O
,	O
loss	O
of	O
appetite	O
,	O
sleep	B-DS
disorders	I-DS
,	O
circadian	B-DS
rhythm	I-DS
disorders	I-DS
,	O
and	O
so	O
on	O
in	O
depression	B-DS
[	O
32	O
].	O

Dopamine	O
(	O
DA	O
)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
motivation	O
,	O
volition	O
,	O
interest	O
/	O
pleasure	O
,	O
and	O
attention	O
/	O
concentration	O
,	O
all	O
of	O
which	O
are	O
likely	O
to	O
be	O
impaired	O
in	O
depressed	O
patients	O
.	O

Several	O
previous	O
reports	O
have	O
suggested	O
that	O
depression	B-DS
may	O
often	O
be	O
accompanied	O
by	O
a	O
relative	O
hypodopaminergic	O
state	O
[	O
33	O
].	O

According	O
to	O
the	O
“	O
monoamine	O
hypothesis	O
,”	O
the	O
decreased	O
releasing	O
and	O
lower	O
contents	O
in	O
the	O
synapse	O
of	O
5	O
-	O
HT	O
,	O
DA	O
,	O
or	O
NE	O
in	O
central	O
nervous	O
system	O
are	O
involved	O
in	O
pathogenesis	O
of	O
depression	B-DS
.	O

Thus	O
,	O
it	O
is	O
well	O
known	O
that	O
many	O
antidepressant	O
drugs	O
currently	O
in	O
use	O
exert	O
effects	O
by	O
regulating	O
the	O
reuptake	O
and	O
metabolic	O
balance	O
of	O
monoamine	O
neurotransmitters	O
[	O
34	O
].	O

Our	O
experimental	O
results	O
showed	O
that	O
the	O
5	O
-	O
HT	O
and	O
DA	O
contents	O
significantly	O
decreased	O
,	O
while	O
the	O
NE	O
content	O
and	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
significantly	O
increased	O
in	O
hippocampus	O
in	O
rats	B-OG
,	O
accompanied	O
by	O
the	O
depressive	O
-	O
like	O
behavioral	O
alterations	O
,	O
which	O
confirm	O
that	O
the	O
dysfunction	O
of	O
monoamine	O
neurotransmitters	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
depression	B-DS
.	O

Amino	O
acid	O
neurotransmitters	O
can	O
be	O
divided	O
into	O
two	O
types	O
of	O
excitatory	O
amino	O
acid	O
and	O
inhibitory	O
amino	O
acid	O
;	O
the	O
former	O
includes	O
Glu	O
and	O
Asp	O
,	O
while	O
GABA	O
and	O
Tau	O
belong	O
to	O
the	O
latter	O
.	O

Some	O
of	O
the	O
studies	O
,	O
whether	O
in	O
rodent	O
models	O
of	O
depression	B-DS
or	O
in	O
depressed	O
patients	O
,	O
indicate	O
that	O
the	O
increase	O
of	O
the	O
Glu	O
concentration	O
is	O
closely	O
related	O
to	O
depression	B-DS
[	O
35	O
].	O

As	O
an	O
important	O
inhibitory	O
neurotransmitter	O
in	O
the	O
brain	O
,	O
GABA	O
decreases	O
significantly	O
in	O
the	O
patients	O
of	O
depression	B-DS
[	O
36	O
].	O

Therefore	O
,	O
the	O
change	O
of	O
the	O
ratio	O
of	O
excitatory	O
/	O
inhibitory	O
amino	O
acid	O
in	O
the	O
brain	O
has	O
an	O
important	O
influence	O
on	O
the	O
incidence	O
of	O
depression	B-DS
[	O
37	O
].	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
significantly	O
increased	O
,	O
while	O
the	O
GABA	O
and	O
Tau	O
contents	O
decreased	O
in	O
hippocampus	O
in	O
depressed	O
rats	B-OG
;	O
it	O
is	O
suggested	O
that	O
CUMS	O
could	O
lead	O
to	O
the	O
imbalance	O
of	O
excitatory	O
/	O
inhibitory	O
amino	O
acids	O
in	O
the	O
brain	O
,	O
which	O
may	O
account	O
for	O
the	O
mechanism	O
underlying	O
the	O
behavioral	O
changes	O
in	O
rats	B-OG
.	O

In	O
the	O
rat	B-OG
and	O
other	O
mammalian	O
species	O
,	O
including	O
human	B-OG
beings	O
,	O
HPA	O
axis	O
and	O
neurotransmitters	O
system	O
are	O
closely	O
interacted	O
in	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
(	O
particularly	O
in	O
hippocampus	O
)	O
and	O
greatly	O
involved	O
in	O
stress	B-DS
related	I-DS
disorder	I-DS
[	O
38	O
,	O
39	O
].	O

Under	O
the	O
chronic	O
stress	O
,	O
as	O
high	O
concentration	O
of	O
GC	O
could	O
induce	O
the	O
liver	O
to	O
produce	O
tryptophan	B-GP
pyrrole	I-GP
enzyme	I-GP
,	O
it	O
could	O
degrade	O
the	O
tryptophan	O
in	O
the	O
blood	O
.	O

Tryptophan	O
is	O
the	O
precursor	O
of	O
5	O
-	O
HT	O
and	O
its	O
reduction	O
could	O
lead	O
to	O
synthesis	O
of	O
5	O
-	O
HT	O
and	O
so	O
lead	O
to	O
5	O
-	O
HT	O
content	O
decrease	O
in	O
the	O
brain	O
,	O
thus	O
causing	O
depressive	O
symptoms	O
[	O
40	O
].	O

In	O
a	O
stress	O
state	O
,	O
HPA	O
axis	O
function	O
becomes	O
hyperactive	O
and	O
5	O
-	O
HT	O
synthesis	O
significantly	O
decreases	O
as	O
a	O
result	O
of	O
insufficient	O
tryptophan	O
transported	O
into	O
the	O
CNS	O
[	O
41	O
].	O

Moreover	O
,	O
high	O
concentration	O
of	O
GC	O
can	O
make	O
5	B-GP
-	I-GP
HT	I-GP
transporter	I-GP
(	O
5	B-GP
-	I-GP
HTT	I-GP
)	O
expression	O
increase	O
in	O
hippocampus	O
,	O
amygdala	O
,	O
dorsal	O
raphe	O
nucleus	O
,	O
and	O
other	O
brain	O
areas	O
by	O
GR	B-GP
dependent	O
manner	O
.	O

The	O
increased	O
5	B-GP
-	I-GP
HTT	I-GP
will	O
increase	O
the	O
reuptake	O
of	O
5	O
-	O
HT	O
in	O
synaptic	O
cleft	O
,	O
which	O
aggravates	O
the	O
decrease	O
of	O
5	O
-	O
HT	O
concentration	O
and	O
the	O
severity	O
of	O
the	O
symptoms	O
in	O
depressed	O
patients	O
[	O
42	O
].	O

Stress	O
can	O
affect	O
the	O
excitability	O
of	O
neurons	O
of	O
locus	O
coeruleus	O
(	O
LC	O
),	O
raphe	O
nucleus	O
,	O
and	O
substantia	O
nigra	O
by	O
HPA	O
axis	O
and	O
5	O
-	O
HT	O
and	O
NE	O
/	O
DA	O
play	O
an	O
important	O
role	O
in	O
the	O
change	O
of	O
emotion	O
and	O
mood	O
[	O
43	O
].	O

In	O
the	O
study	O
of	O
social	O
stress	O
in	O
mice	B-OG
,	O
by	O
using	O
the	O
intracellular	O
recording	O
technique	O
in	O
vitro	O
,	O
it	O
is	O
found	O
that	O
CRH	B-GP
can	O
directly	O
activate	O
noradrenergic	O
neurons	O
of	O
the	O
LC	O
,	O
thus	O
resulting	O
in	O
the	O
increase	O
of	O
NE	O
in	O
the	O
brain	O
[	O
44	O
].	O

In	O
addition	O
,	O
some	O
of	O
the	O
studies	O
indicate	O
that	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
can	O
stimulate	O
the	O
hypothalamus	O
to	O
secret	O
CRH	B-GP
,	O
which	O
suggest	O
that	O
a	O
positive	O
feedback	O
neural	O
circuit	O
exists	O
between	O
hypothalamic	O
neurons	O
and	O
neurons	O
secreting	O
5	O
-	O
HT	O
,	O
DA	O
,	O
and	O
NE	O
[	O
45	O
].	O

In	O
chronic	O
stress	O
,	O
high	O
GC	O
concentration	O
may	O
increase	O
the	O
releasing	O
of	O
excitatory	O
amino	O
acid	O
from	O
the	O
synaptic	O
vesicle	O
of	O
the	O
glutamatergic	O
nerve	O
endings	O
and	O
inhibit	O
its	O
reuptake	O
at	O
the	O
same	O
time	O
,	O
which	O
causes	O
the	O
persistent	O
increase	O
of	O
excitatory	O
amino	O
acid	O
[	O
46	O
].	O

The	O
accumulation	O
of	O
Glu	O
can	O
cause	O
hippocampal	O
toxicity	O
,	O
and	O
the	O
high	O
level	O
of	O
extracellular	O
Glu	O
may	O
in	O
turn	O
make	O
the	O
HPA	O
axis	O
more	O
hyperactive	O
to	O
secrete	O
more	O
GC	O
[	O
47	O
].	O

Glu	O
directly	O
injected	O
into	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
in	O
hypothalamus	O
could	O
accelerate	O
the	O
release	O
of	O
ACTH	B-GP
[	O
48	O
].	O

GABA	O
could	O
inhibit	O
the	O
releasing	O
of	O
ACTH	B-GP
,	O
CORT	O
,	O
and	O
CRH	B-GP
in	O
hypothalamus	O
and	O
reregulate	O
the	O
hyperactivity	O
of	O
HPA	O
axis	O
;	O
Tau	O
,	O
as	O
an	O
inhibitory	O
amino	O
acid	O
,	O
has	O
the	O
synergistic	O
action	O
with	O
GABA	O
to	O
exert	O
the	O
effect	O
on	O
inhibiting	O
the	O
activation	O
of	O
HPA	O
axis	O
[	O
49	O
,	O
50	O
].	O

Our	O
data	O
indicated	O
that	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
increased	O
the	O
5	O
-	O
HT	O
and	O
DA	O
contents	O
and	O
decreased	O
the	O
NE	O
content	O
in	O
the	O
hippocampus	O
;	O
meanwhile	O
,	O
the	O
ratio	O
of	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
in	O
rats	B-OG
with	O
CUMS	O
could	O
be	O
reversed	O
by	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
),	O
which	O
may	O
account	O
for	O
primary	O
monoamine	O
neurotransmitters	O
regulating	O
mechanism	O
underlying	O
DZXYS	O
antidepressant	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
although	O
having	O
no	O
effects	O
on	O
GABA	O
and	O
Tau	O
,	O
FA	O
(	O
0	O
.	O
172	O
g	O
/	O
kg	O
)	O
and	O
FB	O
(	O
3	O
.	O
608	O
g	O
/	O
kg	O
)	O
significantly	O
decreased	O
the	O
contents	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
,	O
which	O
suggested	O
that	O
DZXYS	O
could	O
reduce	O
the	O
excitatory	O
toxicity	O
caused	O
by	O
the	O
accumulation	O
of	O
Glu	O
and	O
Asp	O
in	O
hippocampus	O
in	O
depressed	O
rats	B-OG
,	O
partly	O
regulating	O
the	O
imbalance	O
of	O
the	O
ratio	O
of	O
excitatory	O
/	O
inhibitory	O
amino	O
acid	O
that	O
may	O
be	O
involved	O
in	O
its	O
antidepressant	O
effects	O
.	O

There	O
is	O
a	O
close	O
relationship	O
between	O
HAP	O
and	O
neurotransmitters	O
in	O
regulating	O
emotion	O
and	O
behavior	O
in	O
depression	B-DS
[	O
51	O
].	O

As	O
observed	O
in	O
our	O
experiment	O
,	O
it	O
could	O
be	O
speculated	O
that	O
the	O
amelioration	O
produced	O
by	O
DZXYS	O
on	O
the	O
neurotransmitter	O
system	O
may	O
be	O
associated	O
with	O
its	O
effect	O
on	O
HPA	O
axis	O
.	O

However	O
,	O
the	O
cellular	O
and	O
molecular	O
biological	O
mechanism	O
of	O
exerting	O
regulating	O
effect	O
of	O
DZXYS	O
between	O
the	O
HPA	O
axis	O
and	O
neurotransmitters	O
remains	O
to	O
be	O
further	O
studied	O
in	O
the	O
future	O
.	O

In	O
conclusion	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
antidepressant	O
effects	O
of	O
two	O
fractions	O
(	O
petroleum	O
ether	O
soluble	O
fraction	O
,	O
FA	O
,	O
and	O
water	O
-	O
EtOH	O
soluble	O
fraction	O
,	O
FB	O
)	O
prepared	O
from	O
DZXYS	O
were	O
observed	O
.	O

The	O
results	O
demonstrated	O
that	O
DZXYS	O
could	O
ameliorate	O
the	O
depression	B-DS
-	O
like	O
behavior	O
in	O
chronic	O
stress	O
model	O
of	O
rats	B-OG
.	O

The	O
mechanisms	O
of	O
action	O
of	O
DZXYS	O
might	O
be	O
accounted	O
for	O
by	O
inhibiting	O
hyperactivity	O
of	O
HPA	O
axis	O
and	O
modulating	O
monoamine	O
and	O
amino	O
acid	O
neurotransmitters	O
in	O
the	O
hippocampus	O
.	O

Thus	O
,	O
we	O
confirmed	O
that	O
DZXYS	O
has	O
the	O
potential	O
to	O
be	O
a	O
beneficial	O
remedy	O
for	O
the	O
treatment	O
of	O
depression	B-DS
.	O

Because	O
of	O
multiple	O
using	O
of	O
plants	B-OG
in	O
a	O
traditional	O
herbal	O
medicine	O
and	O
the	O
complexity	O
of	O
the	O
pathological	O
mechanism	O
of	O
depression	B-DS
,	O
it	O
is	O
undoubted	O
that	O
there	O
exist	O
more	O
other	O
active	O
fractions	O
from	O
DZXYS	O
and	O
further	O
regulatory	O
mechanisms	O
of	O
DZXYS	O
in	O
antidepression	O
.	O

These	O
works	O
are	O
currently	O
being	O
conducted	O
in	O
our	O
laboratory	O
.	O

Schedule	O
of	O
chronic	O
unpredictable	O
mild	O
stress	O
(	O
CUMS	O
)	O
procedure	O
.	O

The	O
CUMS	O
protocol	O
consisted	O
of	O
the	O
sequential	O
application	O
of	O
a	O
variety	O
of	O
unpredictable	O
mild	O
stressors	O
.	O

These	O
stressors	O
were	O
randomly	O
scheduled	O
over	O
a	O
one	O
-	O
week	O
period	O
from	O
day	O
1	O
to	O
day	O
7	O
and	O
repeated	O
for	O
4	O
weeks	O
during	O
the	O
entire	O
experiment	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
sucrose	O
consumption	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
FST	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
TST	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
duration	O
of	O
immobility	O
in	O
OFT	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
DA	O
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
NE	O
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

The	O
effect	O
of	O
DZXYS	O
(	O
FA	O
at	O
0	O
.	O
086	O
and	O
0	O
.	O
172	O
g	O
/	O
kg	O
and	O
FB	O
at	O
1	O
.	O
804	O
and	O
3	O
.	O
608	O
g	O
/	O
kg	O
,	O
intragastrically	O
)	O
on	O
the	O
contents	O
of	O
Glu	O
,	O
Asp	O
,	O
GABA	O
,	O
and	O
Tau	O
in	O
hippocampus	O
in	O
rats	B-OG
with	O
chronic	O
unpredictable	O
mild	O
stress	O
.	O

IMI	O
at	O
daily	O
dosage	O
of	O
20	O
mg	O
/	O
kg	O
was	O
set	O
as	O
a	O
positive	O
control	O
.	O

Each	O
column	O
represents	O
the	O
mean	O
±	O
SD	O
,	O
n	O
=	O
10	O
.	O
∗	O
P	O
<	O
0	O
.	O
05	O
and	O
∗∗	O
P	O
<	O
0	O
.	O
01	O
as	O
compared	O
with	O
control	O
group	O
;	O
#	O
P	O
<	O
0	O
.	O
05	O
and	O
##	O
P	O
<	O
0	O
.	O
01	O
,	O
as	O
compared	O
with	O
CUMS	O
group	O
.	O

Different	O
components	O
in	O
the	O
formula	O
of	O
DZXYS	O
.	O

Pharmaceutical	O
name	O

Family	O
name	O

Plant	B-OG
part	O

Chinese	O
name	O

Radix	O
Bupleuri	O

Umbelliferae	B-OG

Root	O

Chai	O
hu	O

Paeoniae	B-OG
Radix	O
Alba	O

Ranunculaceae	B-OG

Root	O

Bai	O
shao	O

Angelica	B-OG
sinensis	I-OG

Umbelliferae	B-OG

Root	O

Dang	O
gui	O

Bighead	O
atractylodes	B-OG
rhizome	O

Compositae	O

Rhizoma	O

Bai	O
zhu	O

Poria	B-OG
cocos	I-OG

Polyporaceae	O

Sclerotium	O

Fu	O
ling	O

Bark	O
of	O
tree	B-OG
peony	I-OG
root	O

Ranunculaceae	B-OG

Root	O
-	O
bark	O

Mu	O
dan	O
pi	O

Fructus	O
Gardeniae	B-OG

Rubiaceae	O

Fruit	O

Zhi	O
zi	O

Mentha	B-OG
haplocalyx	I-OG

Lamiaceae	O

Leaf	O

Bo	O
he	O

Licorice	B-OG

Leguminosae	O

Root	O

Gan	O
cao	O

The	O
contents	O
of	O
CORT	O
,	O
CRH	B-GP
,	O
and	O
ACTH	B-GP
in	O
plasma	O
and	O
hypothalamus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

CORT	O

CRH	B-GP

ACTH	B-GP

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
ng	O
/	O
g	O
)	O

Plasma	O
(	O
ng	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
ng	O
/	O
g	O
)	O

Control	O

—	O

12	O
.	O
60	O
±	O
6	O
.	O
88	O

3	O
.	O
31	O
±	O
0	O
.	O
64	O

20	O
.	O
65	O
±	O
12	O
.	O
52	O

42	O
.	O
11	O
±	O
19	O
.	O
55	O

19	O
.	O
65	O
±	O
8	O
.	O
97	O

CUMS	O

—	O

22	O
.	O
69	O
±	O
13	O
.	O
49	O
∗	O

7	O
.	O
38	O
±	O
1	O
.	O
78	O
∗	O

36	O
.	O
74	O
±	O
8	O
.	O
73	O
∗	O

51	O
.	O
44	O
±	O
25	O
.	O
80	O
∗	O

22	O
.	O
79	O
±	O
7	O
.	O
33	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

22	O
.	O
32	O
±	O
13	O
.	O
31	O

7	O
.	O
37	O
±	O
1	O
.	O
63	O

35	O
.	O
35	O
±	O
8	O
.	O
02	O

50	O
.	O
56	O
±	O
24	O
.	O
71	O

22	O
.	O
42	O
±	O
7	O
.	O
32	O

0	O
.	O
172	O

14	O
.	O
74	O
±	O
10	O
.	O
30	O
##	O

5	O
.	O
33	O
±	O
0	O
.	O
79	O
#	O

23	O
.	O
02	O
±	O
12	O
.	O
8	O
##	O

46	O
.	O
83	O
±	O
23	O
.	O
32	O
##	O

20	O
.	O
83	O
±	O
6	O
.	O
92	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

20	O
.	O
00	O
±	O
6	O
.	O
71	O

7	O
.	O
25	O
±	O
1	O
.	O
77	O

33	O
.	O
36	O
±	O
10	O
.	O
57	O

51	O
.	O
32	O
±	O
10	O
.	O
28	O

22	O
.	O
26	O
±	O
9	O
.	O
20	O

3	O
.	O
608	O

10	O
.	O
91	O
±	O
3	O
.	O
30	O
##	O

3	O
.	O
95	O
±	O
0	O
.	O
12	O
##	O

16	O
.	O
04	O
±	O
9	O
.	O
34	O
##	O

44	O
.	O
47	O
±	O
20	O
.	O
31	O
#	O

20	O
.	O
59	O
±	O
6	O
.	O
88	O
#	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

10	O
.	O
23	O
±	O
3	O
.	O
21	O
##	O

3	O
.	O
67	O
±	O
0	O
.	O
13	O
##	O

15	O
.	O
44	O
±	O
9	O
.	O
02	O
##	O

42	O
.	O
26	O
±	O
20	O
.	O
01	O
##	O

19	O
.	O
13	O
±	O
6	O
.	O
76	O
##	O

The	O
AVP	O
contents	O
in	O
plasma	O
and	O
hypothalamus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

AVP	O

Plasma	O
(	O
pg	O
/	O
mL	O
)	O

Hypothalamus	O
(	O
pg	O
/	O
mg	O
)	O

Control	O

—	O

14	O
.	O
70	O
±	O
4	O
.	O
80	O

58	O
.	O
50	O
±	O
17	O
.	O
80	O

CUMS	O

—	O

25	O
.	O
20	O
±	O
7	O
.	O
30	O
∗	O

309	O
.	O
20	O
±	O
70	O
.	O
41	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

24	O
.	O
23	O
±	O
7	O
.	O
12	O

306	O
.	O
20	O
±	O
70	O
.	O
33	O

0	O
.	O
172	O

12	O
.	O
60	O
±	O
3	O
.	O
20	O
#	O

267	O
.	O
40	O
±	O
58	O
.	O
60	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

23	O
.	O
74	O
±	O
7	O
.	O
10	O

301	O
.	O
60	O
±	O
70	O
.	O
70	O

3	O
.	O
608	O

12	O
.	O
30	O
±	O
3	O
.	O
40	O
##	O

173	O
.	O
20	O
±	O
20	O
.	O
90	O
##	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

11	O
.	O
21	O
±	O
3	O
.	O
12	O
##	O

168	O
.	O
53	O
±	O
20	O
.	O
11	O
##	O

The	O
contents	O
of	O
5	O
-	O
HT	O
,	O
5	O
-	O
HIAA	O
,	O
and	O
5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O
ratio	O
in	O
hippocampus	O
in	O
each	O
group	O
.	O

Group	O

Dose	O

5	O
-	O
HT	O
(	O
ng	O
/	O
g	O
wet	O
tissue	O
)	O

5	O
-	O
HIAA	O
(	O
ng	O
/	O
g	O
wet	O
tissue	O
)	O

5	O
-	O
HIAA	O
/	O
5	O
-	O
HT	O

Control	O

—	O

428	O
.	O
3	O
±	O
171	O
.	O
2	O

376	O
.	O
3	O
±	O
210	O
.	O
3	O

1	O
.	O
04	O
±	O
0	O
.	O
41	O

CUMS	O

—	O

213	O
.	O
7	O
±	O
142	O
.	O
4	O
∗∗	O

387	O
.	O
6	O
±	O
146	O
.	O
6	O

1	O
.	O
62	O
±	O
0	O
.	O
82	O
∗	O

FA	O
(	O
g	O
/	O
kg	O
)	O

0	O
.	O
086	O

262	O
.	O
5	O
±	O
145	O
.	O
8	O

370	O
.	O
6	O
±	O
107	O
.	O
8	O

1	O
.	O
58	O
±	O
0	O
.	O
83	O

0	O
.	O
172	O

447	O
.	O
8	O
±	O
236	O
.	O
7	O
#	O

436	O
.	O
8	O
±	O
311	O
.	O
2	O

1	O
.	O
02	O
±	O
0	O
.	O
46	O
#	O

FB	O
(	O
g	O
/	O
kg	O
)	O

1	O
.	O
804	O

301	O
.	O
2	O
±	O
146	O
.	O
5	O

378	O
.	O
7	O
±	O
118	O
.	O
1	O

1	O
.	O
57	O
±	O
0	O
.	O
79	O

3	O
.	O
608	O

468	O
.	O
2	O
±	O
139	O
.	O
3	O
##	O

487	O
.	O
2	O
±	O
83	O
.	O
2	O
#	O

0	O
.	O
97	O
±	O
0	O
.	O
56	O
#	O

IMI	O
(	O
mg	O
/	O
kg	O
)	O

20	O

479	O
.	O
5	O
±	O
148	O
.	O
7	O
##	O

509	O
.	O
3	O
±	O
84	O
.	O
7	O
#	O

1	O
.	O
01	O
±	O
0	O
.	O
33	O
#	O

